A specific HDAC inhibitor, MS-275, has been shown to significantly reduce tumor growth, decrease VWF-positive blood vessels, decrease lung metastasis and reverse epithelial-mesenchymal transition in an in vivo murine model of breast cancer [162]. The gene discussed is VWF; the disease is breast carcinoma.